Issue 77, 2020

Intracellular delivery of therapeutic proteins through N-terminal site-specific modification

Abstract

A versatile strategy for the intracellular delivery of functional proteins/antibodies was developed using N-terminal site-specific modification. Adopting orthogonal dual-labeling strategies, a cell-permeable RNase A prodrug was designed complementing N-terminal site-specific modification with lysine labeling. Upon successful cytosolic uptake, the prodrug showed reactive oxygen species (ROS)-dependent targeted cancer therapy.

Graphical abstract: Intracellular delivery of therapeutic proteins through N-terminal site-specific modification

Supplementary files

Article information

Article type
Communication
Submitted
08 Jul 2020
Accepted
19 Aug 2020
First published
19 Aug 2020

Chem. Commun., 2020,56, 11473-11476

Intracellular delivery of therapeutic proteins through N-terminal site-specific modification

S. S. Liew, C. Zhang, J. Zhang, H. Sun, L. Li and S. Q. Yao, Chem. Commun., 2020, 56, 11473 DOI: 10.1039/D0CC04728G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements